Latest Headlines

Latest Headlines

GE backs depression neurostim startup Neuronetics in $34M Series F round

Neuronetics has closed a $34.3 million Series F round to further commercialize its NeuroStar transcranial magnetic stimulation therapy system to treat drug-resistant major depressive disorder (MDD), as well as to fund a registration study for adolescent use of the device. NeuroStar was cleared by FDA in 2008 to treat MDD, but the company said it's just recently been gaining traction with payers.

Spectranetics shares slump as the medical laser maker snips forecast

Shares of Spectranetics, the maker of medical lasers, hit a 6-month low in heavy trading after it reported lower quarterly earnings and trimmed its forecast for the year because of increased competition from other drug-coated balloon products and its own R&D spending.

Toshiba sees the future in screen-based medical devices

More than 55 years after pioneering the world's first color television set, Toshiba aims to become a healthcare company making medical devices. In that new realm, Toshiba still expects to be dealing with images on a machine.

Mobile health apps haul in $220M in Q1 funding

Mobile health apps raised $220 million in Q1 2015. And the financial backers were ambitious. Fitness, nutrition and wellness apps accounted for only 17% of the total, while advanced apps to treat chronic conditions and illnesses took 77% of the pie.

Biogen sales, profit miss the mark as Tecfidera flags

Remember the days when Biogen's Tecfidera was trumping analyst expectation after analyst expectation? Well, they're in the past--at least for now.

AstraZeneca sales retreat in its effort to achieve huge growth by 2023

AstraZeneca CEO Pascal Soriot, while fighting off the takeover attempt by Pfizer, promised that the company would hit annual revenue of $45 billion by 2023. Now he will be measured by that promise quarter by quarter and today he fell a little short.

Bard's Lutonix drug-coated balloons help lift Q1 earnings

C.R. Bard reported increased first-quarter sales as its Lutonix drug-coated balloons used to treat peripheral artery disease (PAD) in outpatients help lift the company's earnings.

Lilly beats estimates on newly bulked-up animal health unit

Indianapolis-based Eli Lilly said Thursday that it earned 87 cents per share in the first quarter of 2015--10 cents more than analysts had expected--an achievement the company attributed largely to its $5.4 billion acquisition of Novartis Animal Health.

Shanghai Haohai Biological IPO priced near top end, source says

Shanghai Haohai Biological Technology has priced its Hong Kong initial public offering at the top end of an indicative price range of HK$48.50 to HK$59 per share to raise $305 million, better than the $263 million (HK$2.0 billion) expected, according to a source.

Watch out, Big Pharma: A Teva-Mylan combo would remake the industry Top 10

As of 2014, Teva is in the No. 11 spot on the list of pharma's top revenue generators. But if it gets its way and lands a deal for rival generics maker Mylan, just how much will it be moving up the charts?